Radiopharmaceutical biotech companies Nuclidium and Actithera have raised sizable capital rounds to develop novel diagnostic and therapeutic platforms. Swiss-German Nuclidium secured $99 million in Series B funding to advance copper isotope-based radiopharmaceuticals aimed at improved production scalability and supply. Danish company Actithera closed a $75.5 million Series A to progress a candidate targeting fibroblast activation protein (FAP) with small-molecule pharmacokinetics. These investments indicate growing interest in radiopharma innovation for oncology applications.